Pitt Hyde & Mason Hawkins Buy 50% Stake In GTx Ahead Of Phase II Results Apr. 29, 2014 8:40 AM ET
Pitt Hyde & Mason Hawkins Buy 50% Stake In GTx Ahead Of Phase II Results
Apr. 29, 2014 8:40 AM ET | About: GTXI, Includes: AGEN, AZO, ECYT, OXGN
Disclosure: I am long GTXI. (More...)
GTXI has recently seen extraordinary insider buying and outside investment of $38 million.
Investors Pitt Hyde and Mason Hawkins have a successful track record of identifying undervalued companies poised for growth.
New investments in GTXI coincide with imminent catalyst of the release of Phase II trial results for metastatic cancer drug, Enobosarm.
Based on recent, positive Phase II trial results for other cancer drugs in sector, the average near-term gain is 109% post results release.
Pitt Hyde & Mason Hawkins Take Over 50% Stake in GTx Ahead of Phase II Results
In the recent, severe sell-off in biotech stocks, speculative investors are looking for bargains in the sector and signs of a bottom. With so many stocks suffering, it is very hard to navigate the many choices and pick which companies are buys at today's prices. The average retail investor does not have the time to do hours of research on hundreds of companies in their quest to find undervalued gems.